On March 19, 2026, RxSight, Inc. (the "Company") filed an amended Current Report on Form 8-K/A with the Securities and Exchange Commission (SEC) to provide additional details regarding the compensation of its newly appointed Chief Financial Officer, Mark Wilterding. The initial report, filed on January 12, 2026, announced Mr. Wilterding's appointment effective January 11, 2026, but did not include specific compensation figures due to the timing of the determination.

The amendment reveals that Mr. Wilterding's sign-on bonus has been set at $169,348.10, which was finalized on March 10, 2026, and subsequently paid on March 13, 2026, after applicable payroll deductions. Additionally, the filing corrects the vesting schedule of stock options granted to Mr. Wilterding. According to the amended report, 25% of the shares subject to the options will vest on the one-year anniversary of his start date, with the remaining shares vesting monthly over the subsequent three years, culminating in full vesting four years from January 11, 2026, contingent upon his continued employment.

This filing serves to clarify the terms of Mr. Wilterding's compensation package, which is crucial for investors and stakeholders monitoring the company's governance and financial commitments. The amendment does not alter any other disclosures from the initial report, maintaining the integrity of the previously reported information while enhancing transparency regarding executive compensation. As such, the filing is considered administrative in nature, with no expected impact on the company's stock price.



Press Release distribution
National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.